Publication details

GLIOMET DEVELOPMENT SAFETY UPDATE REPORT Období: 4.12.2023 – 20.6.2024

Title in English GLIOMET DEVELOPMENT SAFETY UPDATE REPORT Period Období: 4.12.2023 – 20.6.2024
Authors

DEMLOVÁ Regina NERUŠILOVÁ Kateřina

Year of publication 2024
Type Research report
MU Faculty or unit

Faculty of Medicine

web
Description The fourth periodic report on the GlioMET study evaluates the safety data received by the study sponsor during the period 4.12.2023 to 20.6.2024 The clinical evaluation is monocentric, taking place in the Czech Republic at one center - the Masaryk Institute of Oncology, Brno. Primary brain tumors are less common tumors compared to other oncological diagnoses, with an incidence of 8/100,000 inhabitants. Unfortunately, the most aggressive ones, glioblastomas (GB), account for about half of all primary malignant brain tumors. Due to their biological behavior, these tumors are ranked among the most difficult to treat diseases in general and therefore represent a serious health problem despite their relatively low incidence. Clinical trials evaluating the role of modern targeted therapy and immunotherapy have not yet demonstrated a higher efficacy of this treatment strategy and the results of GB treatment have not fundamentally changed. Patients with diagnosed GB who develop early progression before the start of adjuvant radiotherapy have a very poor prognosis. The purpose of this KH is to refine the diagnosis in patients with GB with proven REP (rapid early progression) and subsequently optimize the planning of further treatment (radiotherapy).

You are running an old browser version. We recommend updating your browser to its latest version.

More info